SMAD7 and Cachexia: Winbanks exhibited this phenomenon through the delivery of Smad7 gene therapy in mouse models of cachexia, as Smad7 functions as an intracellular negative regulator, curbing the activation of Smad2 and Smad3 while promoting the degradation of ActRIIB complexes [180].